Pancreatic Unit, Casa di Cura Pederzoli, Peschiera del Garda (VR), Italy.
HPB (Oxford). 2013 Aug;15(8):623-7. doi: 10.1111/hpb.12027. Epub 2012 Dec 6.
Radiofrequency ablation (RFA) is a relatively new technique, applied to metastatic solid tumours which, in recent studies, has been shown to be feasible and safe on locally advanced pancreatic carcinoma (LAPC). RFA can be combined with radio-chemotherapy (RCT) and intra-arterial plus systemic chemotherapy (IASC). The aim of this study was to investigate the impact on the prognosis of a multimodal approach to LAPC and define the best timing of RFA.
This is a retrospective observational study of patients who have consecutively undergone RFA associated with multiple adjuvant approaches.
Between February 2007 and December 2011, 168 consecutive patients were treated by RFA, of which 107 were eligible for at least 18 months of follow-up. Forty-seven patients (group 1) underwent RFA as an up-front treatment and 60 patients as second treatment (group 2) depending on clinician choice. The median overall survival (OS) of the whole series was 25.6 months: 14.7 months in the group 1 and 25.6 months in the group 2 (P = 0.004). Those patients who received the multimodal treatment (RFA, RCT and IASC-triple approach strategy) had an OS of 34.0 months.
The multimodal approach seems to be feasible and associated with an improved longer survival rate.
射频消融 (RFA) 是一种相对较新的技术，适用于转移性实体肿瘤，最近的研究表明，该技术对局部晚期胰腺癌 (LAPC) 是可行且安全的。RFA 可以与放射化学疗法 (RCT) 和经动脉内加全身化疗 (IASC) 联合使用。本研究旨在探讨多模式治疗 LAPC 对预后的影响，并确定 RFA 的最佳时机。
这是一项回顾性观察性研究，纳入了连续接受 RFA 联合多种辅助治疗的患者。
在 2007 年 2 月至 2011 年 12 月期间，168 例连续患者接受了 RFA 治疗，其中 107 例至少随访 18 个月。47 例患者 (组 1) 作为一线治疗接受 RFA，60 例患者 (组 2) 作为二线治疗，由临床医生选择。全组中位总生存期 (OS) 为 25.6 个月：组 1 为 14.7 个月，组 2 为 25.6 个月 (P = 0.004)。接受多模式治疗 (RFA、RCT 和 IASC-三联治疗策略) 的患者 OS 为 34.0 个月。
多模式治疗似乎是可行的，并与更长的生存率提高相关。
